Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by INC Research
Apotex Inc.
Aurobindo Pharma
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
Hoffmann-La Roche
Gilead Sciences
Hetero Labs Ltd.
Janssen R&D Ireland
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Mylan Laboratories
Novartis Pharmaceuticals
Prinston Pharmaceutical Inc.
Ranbaxy Inc.
Sciegen Pharmaceuticals Inc.
Sigmapharm Laboratories
Silarx Pharmaceuticals Inc
Strides Arcolab Ltd.
Sunshine Lake Pharma
Teva Pharmaceuticals USA
ViiV Healthcare
Alvogen Korea
Amneal Pharmaceuticals, LLC
West-Ward Pharmaceuticals Corporation
Information provided by (Responsible Party):
INC Research Identifier:
First received: November 27, 2006
Last updated: June 28, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2099
  Estimated Primary Completion Date: January 2099 (Final data collection date for primary outcome measure)